Ascletis Pharma (HKG:1672) will present data from its 28-day multiple ascending dose study of ASC30 in an oral discussion at the 61st European Association for the Study of Diabetes Annual Meeting in Vienna, Austria, a Tuesday Hong Kong bourse filing said.
The drug demonstrated superior weight loss in participants with obesity in the relevant study.